S.R. Walker – författare
Visar alla böcker från författaren S.R. Walker. Handla med fri frakt och snabb leverans.
21 produkter
Improving the Regulatory Review Process
Industry and Regulatory Initiatives
Av C. Lumley, S.R. Walker
Inbunden, 1996
1692 kr
Lägg i varukorg
Regulatory review is the last major development hurdle that must be passed by a new medicine before it reaches the market. At a time when pharmaceutical companies are reviewing their R&D strategies, and attempting to reduce drug development times, it is extremely important that the review process …
Timing of Toxicological Studies to Support Clinical Trials
Av C. Parkinson, N. McAuslane m. fl.
Inbunden, 1995
1130 kr
Lägg i varukorg
The timing of toxicological studies in relation to the clinical evaluation of new medicines is a key topic for strategic planners in the industry and those involved with harmonization. Resolving the anomalies between different regulatory authorities should eliminate redundant testing on animals and …
Trends and Changes in Drug Research and Development
Av Society for Drug Research, Bryan Ed Walker m. fl.
Inbunden, 1989
1130 kr
Lägg i varukorg
The 20th Anniversary of a Learned Society is a momentous event in its af fairs, and it is fitting that, in the Appendix to the Proceedings of the 20th An niversary Meeting, the history of the Society for Drug Research is outlined. The aim of the Society, to encourage an interdisciplinary approach …
Monitoring for Adverse Drug Reactions
Av S.R. Walker, Abraham Goldberg
Inbunden, 1985
2252 kr
Lägg i varukorg
Long-Term Animal Studies
Their Predictive Value for Man
Av S.R. Walker, Anthony D. Dayan
Inbunden, 1986
2252 kr
Lägg i varukorg
International Medicines Regulations
A Forward Look to 1992
E-bok, 2012
675 kr
Lägg i varukorg
As 1992 looms on the horizon and preparation is made for the completion of the internal market in Europe, the CMR realised the value of addressing some of the issues involved and defining the objectives and achievements of medicines regulations in a number of EEC countries in comparison with Japan …
Improving the Regulatory Review Process
Industry and Regulatory Initiatives
Av S.R. Walker, C. Lumley
E-bok, 2012
1942 kr
Lägg i varukorg
Regulatory review is the last major development hurdle that must be passed by a new medicine before it reaches the market. At a time when pharmaceutical companies are reviewing their R&D strategies, and attempting to reduce drug development times, it is extremely important that the review process …
Trends and Changes in Drug Research and Development
Av S.R. Walker
E-bok, 2012
1502 kr
Lägg i varukorg
The 20th Anniversary of a Learned Society is a momentous event in its af fairs, and it is fitting that, in the Appendix to the Proceedings of the 20th An niversary Meeting, the history of the Society for Drug Research is outlined. The aim of the Society, to encourage an interdisciplinary approach …
Medicines and Risk/Benefit Decisions
E-bok, 2012
755 kr
Lägg i varukorg
The third CMR Workshop prov. ided the opportunity for a group of experts from the Industry, academia and the regulatory authorities to meet and discuss ways and means by which risk benefit decisions are made during the various stages of drug development. It became apparent from the discussions that …
Relevance of Ethnic Factors in the Clinical Evaluation of Medicines
Proceedings of a Workshop held at The Medical Society of London, UK, 7th and 8th July, 1993
Av S.R. Walker, C. Lumley m. fl.
Häftad, 2012
569 kr
Lägg i varukorg
For a research-based pharmaceutical company to be successful in the 1990s. it must have a strategic plan for the global development of new chemical entities. Global development can be defined as an attempt to reach all major markets as rapidly as possible and for many companies these will include …
Timing of Toxicological Studies to Support Clinical Trials
Av C. Parkinson, N. McAuslane m. fl.
Häftad, 2012
1128 kr
Lägg i varukorg
Over the past twelve years, the Centre for Medicines Research has held a series of Workshops on a number of topics related to the drug discovery and development process. The major objective of these Workshops has been to provide an international forum for regula tory, academic and industry …
Quality of Life Assessment: Key Issues in the 1990s
Av S.R. Walker, Rachel M. Rosser
Häftad, 2012
569 kr
Lägg i varukorg
It was over five years ago that the Centre for Medicines Research organized a workshop entitled "Quality of Life: Assessment and Application". This workshop brought together a unique group of participants, some of whom had been involved in studies on quality of life for well over a decade, whilst …
Improving the Regulatory Review Process: Assessing Performance and Setting Targets
Häftad, 2012
508 kr
Lägg i varukorg
At a time when it is becoming usual for medicines to be developed for a global market and pharmaceutical companies are endeavouring to expedite the drug development process, Regulatory Authorities are concentrating on improving their efficiency and effectiveness. Therefore, it is not surprising …
International Medicines Regulations
A Forward Look to 1992
Häftad, 2011
508 kr
Lägg i varukorg
As 1992 looms on the horizon and preparation is made for the completion of the internal market in Europe, the CMR realised the value of addressing some of the issues involved and defining the objectives and achievements of medicines regulations in a number of EEC countries in comparison with Japan …
Improving the Regulatory Review Process
Industry and Regulatory Initiatives
Av C. Lumley, S.R. Walker
Häftad, 2011
1511 kr
Lägg i varukorg
Regulatory review is the last major development hurdle that must be passed by a new medicine before it reaches the market. At a time when pharmaceutical companies are reviewing their R&D strategies, and attempting to reduce drug development times, it is extremely important that the review process …
Trends and Changes in Drug Research and Development
Av S.R. Walker
Häftad, 2011
1128 kr
Lägg i varukorg
The 20th Anniversary of a Learned Society is a momentous event in its af fairs, and it is fitting that, in the Appendix to the Proceedings of the 20th An niversary Meeting, the history of the Society for Drug Research is outlined. The aim of the Society, to encourage an interdisciplinary approach …
Medicines and Risk/Benefit Decisions
Häftad, 2011
569 kr
Lägg i varukorg
The third CMR Workshop prov. ided the opportunity for a group of experts from the Industry, academia and the regulatory authorities to meet and discuss ways and means by which risk benefit decisions are made during the various stages of drug development. It became apparent from the discussions that …
Relevance of Ethnic Factors in the Clinical Evaluation of Medicines
Proceedings of a Workshop held at The Medical Society of London, UK, 7th and 8th July, 1993
Av N. McAuslane, C. Lumley m. fl.
E-bok, 2012
755 kr
Lägg i varukorg
For a research-based pharmaceutical company to be successful in the 1990s. it must have a strategic plan for the global development of new chemical entities. Global development can be defined as an attempt to reach all major markets as rapidly as possible and for many companies these will include …
Timing of Toxicological Studies to Support Clinical Trials
Av S.R. Walker, C. Lumley m. fl.
E-bok, 2012
1502 kr
Lägg i varukorg
Over the past twelve years, the Centre for Medicines Research has held a series of Workshops on a number of topics related to the drug discovery and development process. The major objective of these Workshops has been to provide an international forum for regula tory, academic and industry …
Quality of Life Assessment: Key Issues in the 1990s
Av Rachel M. Rosser, S.R. Walker
E-bok, 2012
755 kr
Lägg i varukorg
It was over five years ago that the Centre for Medicines Research organized a workshop entitled "Quality of Life: Assessment and Application". This workshop brought together a unique group of participants, some of whom had been involved in studies on quality of life for well over a decade, whilst …
Improving the Regulatory Review Process: Assessing Performance and Setting Targets
E-bok, 2012
675 kr
Lägg i varukorg
At a time when it is becoming usual for medicines to be developed for a global market and pharmaceutical companies are endeavouring to expedite the drug development process, Regulatory Authorities are concentrating on improving their efficiency and effectiveness. Therefore, it is not surprising …
